Safety and immunogenicity of a SARS-CoV-2 recombinant protein nanoparticle vaccine (GBP510) adjuvanted with AS03: A randomised, placebo-controlled, observer-blinded phase 1/2 trial.

ABSTRACT:

SUBMITTER: Song JY 

PROVIDER: S-EPMC9304916 | biostudies-literature | 2022 Sep

REPOSITORIES: biostudies-literature